O-082 The ratio AMH/antral follicle count varies according to the etiologies of diminished ovarian reserve suggesting differences in follicular health
Authors: Grynberg M , Lethielleux C , Claire V , Cedrin Durnerin I , Peigné M , Charlotte S 
Published: August 2021

Abstract

Study question
Does diminished ovarian reserve (DOR) and its etiology impact the AMH/AFC ratio?

Summary answer
AMH/AFC ratio varies according to the etiology of DOR in young women, suggesting different impact on the follicular health, and further oocyte quality.

What is known already
Anti-Müllerian hormone and antral follicle count currently represent the two most accurate markers of the follicular ovarian status. Even though they may diagnose a reduction in the follicular stockpile, low values remain inefficient for predicting poor oocyte quality, in particular in young women. Since AMH is produced by the granulosa cells of follicles ranging from primary to small antral follicles, we hypothesized that the etiology of diminished ovarian reserve might differently impact the follicular health and their capacity of producing this peptide.

Study design, size, duration
From November 2018 to December 2021, we conducted a monocentric, retrospective study including a total of 484 infertile patients &lt; 37 years with DOR.

Participants/materials, setting, methods
All patients underwent measurement of AMH levels and AFC. DOR was diagnosed according to the Bologna criteria (AMH &lt; 1.1 ng/mL and AFC &lt; 7). AMH/AFC ratio was compared to values obtained in 154 tubal or male infertility patients matched for age and BMI, with AMH and AFC in the normal ranges. This ratio was studied according to the etiology of DOR: genetic (n = 26), post-chemotherapy (n = 102), idiopathic (n = 215) or ovarian diseases (ovarian cyst or history of ovarian surgery, n = 141).

Main results and the role of chance
Overall, median age of women with DOR was 30 (18-37) years. As expected, age and BMI were comparable in women with DOR and those having normal ovarian reserve tests. In addition, the AMH/AFC ratio failed to show any difference between these 2 groups (0.143 ± 0.22 vs. 0.166 ± 0.11, NS, respectively). Among women with DOR, the etiology was significantly associated with different AMH/AFC ratio. Indeed, patient with DOR of surgical origin (ovarian diseases group) displayed higher mean values (0.283 ± 0.32 ng/mL/ Foll) when compared with those included in genetic (0.079 ± 0.15 ng/mL/ Foll, p &lt; 0.01), idiopathic (0.103 ± 0.16 ng/mL/ Foll, p &lt; 0.03) or post-chemotherapy (0.084 ± 0.20 ng/mL/ Foll, p &lt; 0.01) groups. Moreover, genetic and post-chemotherapy DOR was also associated with lower AMH/AFC ratio in comparison with idiopathic DOR.

Limitations, reasons for caution
Despite interesting results, the retrospective nature of the present study may represent a limitation. Moreover, AMH/AFC ratio constitute an indirect method for assessing per follicle AMH production. We hypothesized that this ratio might reflect the follicular health. Its impact on natural conception and assisted reproductive technologies outcome is not known.

Wider implications of the findings
AMH/AFC ratio may represent an innovative tool aiming to indirectly assess follicular health and possibly oocyte quality in young women with DOR. The etiology of DOR differently impacts the follicular function as reflected by AMH/AFC ratio. Further data on live birth rates following natural or medically assisted pregnancies is needed.

Trial registration number
N/A